Endomag receives CE Mark for Magseed

Wednesday, 13 September, 2017

Endomag announced today that it has received CE Mark approval for Magseed®, a minimally invasive breast marker used to accurately guide surgeons during breast cancer removal. Magseed will be distributed throughout EMEA by Sysmex, as part of a new 5-year distribution deal for the Sentimag®...


Ochsner Health System adopts Magseed

Monday, 8 May, 2017

Endomag announced today that Ochsner Health System has adopted Magseed® as the standard of care for breast lesion localisation, having identified the system as simpler and more effective than alternative techniques. Magseed was chosen as the preferred alternative to wire localisation, based on...

Peter Keen

Endomag Strengthens Board with Key Appointment

Monday, 3 April, 2017

Endomag announced today the appointment of Peter Keen as non-executive director, effective immediately.
Since the launch of Magseed®, Endomag’s breast lesion localisation device, in November 2016, interest has exceed expectations. Over 150 hospitals, including 30 of the top 50...

UCSF Adopts Magseed as Standard of Care

Monday, 23 January, 2017

Endomag announced today that the University of California, San Francisco (UCSF) has become the first US site to adopt Magseed™ as its standard of care for localization of impalpable breast lesions. Magseed™ is a simpler, more effective alternative to traditional wire localization methods.

SABCS 2016 Poster

US Multi-Centre Trial Published at SABCS 2016

Thursday, 8 December, 2016

Endomag announced today that its Sentimag and Sienna system for sentinel lymph node detection in early stage breast cancer has been shown to be non-inferior to the current standard of care in US patients. The announcement follows completion of a multi-centre trial, which commenced in January...


Please select if you are based outside the U.S.A.


Endomag US

Please select if you are based in the U.S.A.